JP2012526775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526775A5 JP2012526775A5 JP2012510301A JP2012510301A JP2012526775A5 JP 2012526775 A5 JP2012526775 A5 JP 2012526775A5 JP 2012510301 A JP2012510301 A JP 2012510301A JP 2012510301 A JP2012510301 A JP 2012510301A JP 2012526775 A5 JP2012526775 A5 JP 2012526775A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical carrier
- depression
- impregnated
- polymeric pharmaceutical
- milnacipran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003937 drug carrier Substances 0.000 claims description 19
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 12
- 229960000600 milnacipran Drugs 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010021703 Indifference Diseases 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 206010042458 Suicidal ideation Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 230000003542 behavioural effect Effects 0.000 claims description 2
- 238000001784 detoxification Methods 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 208000019899 phobic disease Diseases 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 13
- 239000013543 active substance Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 238000010923 batch production Methods 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 claims 1
- XBDUTCVQJHJTQZ-UHFFFAOYSA-L iron(2+) sulfate monohydrate Chemical compound O.[Fe+2].[O-]S([O-])(=O)=O XBDUTCVQJHJTQZ-UHFFFAOYSA-L 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 230000006996 mental state Effects 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000003068 static effect Effects 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 claims 1
- 229960000922 vinflunine Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 206010027977 Morose Diseases 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010026820 marasmus Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0953221A FR2945449B1 (fr) | 2009-05-15 | 2009-05-15 | Procede d'impregnation par co2 supercritique |
| FR0953221 | 2009-05-15 | ||
| PCT/EP2010/056582 WO2010130799A2 (fr) | 2009-05-15 | 2010-05-12 | Procede d'impregnation par co2 supercritique |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526775A JP2012526775A (ja) | 2012-11-01 |
| JP2012526775A5 true JP2012526775A5 (enExample) | 2015-06-25 |
| JP5847704B2 JP5847704B2 (ja) | 2016-01-27 |
Family
ID=41226888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510301A Expired - Fee Related JP5847704B2 (ja) | 2009-05-15 | 2010-05-12 | 超臨界ｃｏ２を用いて含浸する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9028806B2 (enExample) |
| EP (1) | EP2429499B1 (enExample) |
| JP (1) | JP5847704B2 (enExample) |
| KR (1) | KR101752929B1 (enExample) |
| ES (1) | ES2538346T3 (enExample) |
| FR (1) | FR2945449B1 (enExample) |
| WO (1) | WO2010130799A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2974092B1 (fr) * | 2011-04-13 | 2014-12-05 | Commissariat Energie Atomique | Procede de fabrication de composants par pim, base sur l'utilisation de fibres ou fils organiques, avantageusement couplee a l'utilisation de co2 supercritique |
| WO2016127111A1 (en) * | 2015-02-05 | 2016-08-11 | Colorado Can Llc | Purified cbd and cbda, and methods, compositions and products employing cbd or cbda |
| US10403315B2 (en) | 2015-05-06 | 2019-09-03 | Western Digital Technologies, Inc. | Near-field transducer for heat assisted magnetic recording comprising of thermally stable material layer |
| US20180271826A1 (en) * | 2017-03-22 | 2018-09-27 | Colorado Can Llc | Dry powders of cannabinoids and methods for preparing dry powders |
| CN113679691B (zh) * | 2021-07-28 | 2022-12-13 | 内蒙古东绿生态科技研究院有限公司 | 蒙艾中黄酮类物质的微囊包合物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340614A (en) * | 1993-02-11 | 1994-08-23 | Minnesota Mining And Manufacturing Company | Methods of polymer impregnation |
| FR2752732B1 (fr) * | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
| IT1296464B1 (it) * | 1997-11-19 | 1999-06-25 | Vectorpharma Int | Composizioni farmaceutiche in forma di polveri di polimeri reticolati caricati con farmaci e relativo processo di preparazione mediante |
| IT1318404B1 (it) * | 2000-03-17 | 2003-08-25 | Eurand Int | Processo per la preparazione di formulazioni a rilascio accelerato conimpiego di fluidi compressi. |
| CA2611724C (en) * | 2005-06-10 | 2014-07-29 | Pierre Fabre Medicament S.A. | Stabilized milnacipran formulation |
-
2009
- 2009-05-15 FR FR0953221A patent/FR2945449B1/fr not_active Expired - Fee Related
-
2010
- 2010-05-12 WO PCT/EP2010/056582 patent/WO2010130799A2/fr not_active Ceased
- 2010-05-12 JP JP2012510301A patent/JP5847704B2/ja not_active Expired - Fee Related
- 2010-05-12 ES ES10721462.9T patent/ES2538346T3/es active Active
- 2010-05-12 US US13/320,453 patent/US9028806B2/en not_active Expired - Fee Related
- 2010-05-12 EP EP10721462.9A patent/EP2429499B1/fr not_active Not-in-force
- 2010-05-12 KR KR1020117029008A patent/KR101752929B1/ko not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shukla et al. | Hypo-and hyper-assembly diseases of RNA–protein complexes | |
| JP2012526775A5 (enExample) | ||
| JP2008524262A5 (enExample) | ||
| RU2018130727A (ru) | Органические соединения | |
| Kim et al. | Antagonizing neuronal toll-like receptor 2 prevents synucleinopathy by activating autophagy | |
| Mereddy et al. | Benzoboroxoles: Synthesis and applications in medicinal chemistry | |
| ME01090B (me) | Kristalni oblici (r)-8-hloro-metil-2,3,4,5-tetrahidr0-1h-3-benzazepin hlorhidrat | |
| JP2014500249A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2014518275A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2012508275A5 (enExample) | ||
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| Marino et al. | Neuroinflammation: Molecular mechanisms and therapeutic perspectives | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| JP2002525280A5 (enExample) | ||
| JP2010513392A5 (enExample) | ||
| Ebrahimi et al. | The emerging role of noncoding RNAs in neuroinflammation: Implications in pathogenesis and therapeutic approaches | |
| JP2015520238A5 (enExample) | ||
| JP2010508025A5 (enExample) | ||
| JP2007529492A5 (enExample) | ||
| JPWO2020132474A5 (enExample) | ||
| ATE524439T1 (de) | Thiosubstituierte arylmethansulfinylderivate | |
| JP2007521333A5 (enExample) | ||
| JP2010533660A5 (enExample) |